Beyond Single Targets: How Multi-Target Therapies Are Redefining Drug Discovery

Once upon a time, drug discovery meant identifying a single disease-driving target, designing a molecule to inhibit or activate it, and producing a measurable therapeutic response. Although this approach led to groundbreaking oncology, immunology, and rare disease treatments, it has limited effectiveness for complex, adaptive diseases within interconnected biological networks.

Why Target Discovery Still Fails: Fixing The Biology Behind Poor Drug Targets

Target discovery is a common yet often underestimated point of failure in drug development. Even with today’s advanced genomics and computational modeling, the biopharmaceutical industry can still struggle to select targets that leverage biological insights to drive clinical success. Too often, a promising hypothesis crumbles when its foundation is based on incomplete biological understanding, oversimplified disease models, or misinterpreted mechanistic context.

Beyond Hits: The Next Era Of Data-Driven Drug Discovery

Drug discovery is moving beyond traditional hit identification toward data-driven strategies that extract deeper insight from large-scale screening datasets. Advances in DNA-encoded library (DEL) screening, computational tools, and machine learning are helping teams make more informed decisions in early-stage drug development. Access this brand-new Drug Discovery Online content collection for an under-the-hood look at modern approaches to turning large discovery datasets into actionable insight.